Accutane (Isotretinoin) Monitoring Schedule: Labs & Exams

Print or save as PDF

What the label requires before the first capsule

The pre-treatment laboratory instruction in the Absorica and Absorica LD label is one line: complete a fasting lipid profile and liver function tests in all patients [1]. The same label repeats it in its warnings list as 'laboratory monitoring (fasting lipid profile and liver function tests before use)' [1].

Blood count changes do appear in the label, in the adverse reaction section rather than the pre-treatment list: anemia and decreased red cell parameters, decreased white cell counts, thrombocytopenia, increased platelet counts and rare agranulocytosis [1].

Prescribing is also tied to pregnancy status. In patients who can get pregnant, the drug is prescribed only after verification and documentation that the patient is not pregnant [1]. The sequence in the label is a screening pregnancy test in a medical setting, then a confirmatory test in a medical setting at least 30 days after the screening test and after at least 30 days of using the chosen pregnancy prevention method, which is two forms of contraception or committed abstinence [1]. The prescription must be obtained within 7 days of the pregnancy test collection, and pharmacies dispense a maximum 30-day supply with no refills [1].

How often are labs checked during treatment?

The labels give intervals in words. The older-format Accutane label says blood lipid determinations should be performed before the drug is given and then at intervals until the lipid response to the drug is established, which it says usually occurs within 4 weeks [2]. The Absorica label says to monitor lipid levels at regular intervals, and to monitor liver function tests prior to and during treatment [1]. Neither label gives a fixed number of days between tests [1][2].

The Accutane label singles out patients who need closer checking: diabetes, obesity, increased alcohol intake, a lipid metabolism disorder, or a family history of one. For those patients it recommends more frequent checks of serum lipids and/or blood sugar [2].

What the lipid panel shows

In clinical trials reported in the Accutane label, marked triglyceride elevations occurred in approximately 25% of patients receiving the drug, about 15% developed a decrease in high-density lipoprotein cholesterol, and about 7% had an increase in cholesterol [2]. Triglyceride elevations in excess of 800 mg/dL have been reported [2]. In those trials the effects on triglycerides, HDL and cholesterol were reversible when the drug was stopped [2], and some patients reversed triglyceride elevation through weight reduction, restriction of dietary fat and alcohol, and a reduction in dose while continuing treatment [2]. Cheilitis and hypertriglyceridemia are the two adverse reactions the Absorica label calls dose related [1].

The label's stop rule is a judgment, not a number. The Accutane label says the drug should be stopped if hypertriglyceridemia cannot be controlled at an acceptable level or if symptoms of pancreatitis occur [2]. It also says acute pancreatitis has been reported in patients with either elevated or normal serum triglycerides, and rare fatal hemorrhagic pancreatitis has been reported [2]. The Absorica label lists acute pancreatitis under warnings and says to discontinue treatment if pancreatitis symptoms occur [1].

Liver tests

The Absorica label lists hepatotoxicity among its warnings and says liver function tests should be monitored before and during treatment [1]. Its adverse reaction section lists laboratory increases in ALT, AST, GGTP, alkaline phosphatase, bilirubin and LDH [1].

A multicenter, double-blind trial randomized 150 patients with treatment-resistant nodulocystic acne to 0.1, 0.5 or 1 mg/kg/day. All three doses produced a highly significant clinical response with no significant difference in response between them, and clinical side effects and laboratory abnormalities differed only minimally between the groups [3]. Of the patients on 0.1 mg/kg/day, 42% needed another course, and the authors concluded that higher doses are indicated [3].

What is checked by conversation, not by blood draw

Psychiatric symptoms: the label says that before treatment, patients and family members should be asked about any history of psychiatric disorder, and that at each visit during treatment patients should be assessed for depression, mood disturbance, psychosis or aggression [1]. The label says to instruct patients to stop the drug immediately if these develop, and that further evaluation may be necessary [1].

Vision: corneal opacities and decreased night vision appear in the label's ocular warnings, and the label says that if visual symptoms occur, the drug should be discontinued and the patient referred for an ophthalmological exam [1].

Hearing: for hearing impairment, the label says to discontinue and refer to specialized care [1].

Joints and bones: arthralgias, back pain, decreases in bone mineral density and premature epiphyseal closure are listed among the label's musculoskeletal warnings [1].

Digestive and skin: under its inflammatory bowel disease warning the label says to discontinue for abdominal pain, rectal bleeding or severe diarrhea [1]. It also says to monitor for serious skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis, and to discontinue treatment if they occur [1].

iPLEDGE pregnancy testing

Every patient is enrolled in iPLEDGE, and the pregnancy testing and prevention rules differ by whether the patient can get pregnant [1]. For patients who can get pregnant, a pregnancy test is required within 7 days before each prescription, and testing is also required after treatment [1]. Patients who cannot get pregnant must be enrolled in iPLEDGE and must not share isotretinoin [1].

FDA approved modifications to iPLEDGE on 2026-02-09. With prescriber permission, patients may do pregnancy tests outside a medical setting (for example, home tests) during and after treatment, but pre-treatment tests must remain in a medical setting [4][5]. The modifications also remove the waiting period for a repeat test after a missed 7-day prescription window and drop monthly counseling documentation for patients who cannot get pregnant [4][5]. FDA's iPLEDGE page, current as of 2026-06-16, moved the planned implementation date from 2026-08-08 to 2026-11-15 [4]. The Absorica and Absorica LD label dated 2026-08-19 already carries the home-test language [1].

After the last dose

Pregnancy testing is required after treatment as well as before and during it [1]. The label says patients must be informed not to donate blood during treatment and for 1 month after discontinuation, because the blood might be given to a pregnant patient [1].

The label says a second course is not recommended before a 2-month waiting period, because acne may continue to improve after a 15 to 20-week course [1].